FDA Releases Updated Guidance for Early Clinical Trials with Live Biotherapeutic Products

Summary

The FDA has made available a new guidance document that provides recommendations for IND submissions for early clinical trials with live biotherapeutic products in the US, updating previous guidance from 2012 to address when a product label is adequate for CMC information requirements.